TY  - JOUR
A1  - Heimberg, Linda
A1  - Knop, Stefan
T1  - Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
JF  - Oncology Research and Treatment
N2  - Background: With the availability of T-cell-directed therapy and next-generation compounds of established classes of drugs, the treatment of relapsed/refractory (r/r) myeloma is getting more complex. However, treatment options in practice are limited by availability, approval, and patient comorbidity. The aim of this article is to provide a practical approach toward the choice of treatment for r/r myeloma patients. Summary: Regarding market authorization and current guidelines, at least in Germany, most patients nowadays will have received a doublet or triplet combination as first-line therapy containing a proteasome inhibitor and an immunomodulatory drug, mostly lenalidomide. We focus on the treatment options for patients that are ineligible for (another) stem cell transplantation. We will review treatment options for relapse after first- or second-line therapy and beyond third-line. Key Messages: There is promising data supporting the efficacy and safety of triplet combinations containing anti-CD38-monoclonal antibodies (anti-CD38 mAbs) at first or second relapse in combination with next-generation compounds. For the treatment beyond third-line, comparative studies are scarce but some promising compounds are available via conditional authorization, and there is more to come in the future. We will present some early phase trials featuring promising results.
KW  - lenalidomide-refractory patients
KW  - myeloma
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-249773
SN  - 2296-5270
SN  - 2296-5262
VL  - 44
IS  - 12
ER  - 
TY  - JOUR
A1  - Maichl, Daniela Simone
A1  - Kirner, Julius Arthur
A1  - Beck, Susanne
A1  - Cheng, Wen-Hui
A1  - Krug, Melanie
A1  - Kuric, Martin
A1  - Ade, Carsten Patrick
A1  - Bischler, Thorsten
A1  - Jakob, Franz
A1  - Hose, Dirk
A1  - Seckinger, Anja
A1  - Ebert, Regina
A1  - Jundt, Franziska
T1  - Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival
JF  - Blood Cancer Journal
N2  - No abstract available.
KW  - cancer microenvironment
KW  - myeloma
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357598
VL  - 13
ER  -